Nov 21, 2019: SK Life Science new option to treat adults with partial-onset seizures, XCOPRI (cenobamate tablets) approved by FDA which has an often difficult-to-control condition that can have a significant impact on patient quality of life.
Seizures occur when group of nerve cells (neurons) in the brain undergo uncontrolled activation generally for short period of abnormal electrical activity in the brain also uncontrolled movements, abnormal thinking or behavior, and abnormal sensations are reported,Movements can be violent, and changes in consciousness can occur.
XCOPRI causses Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity also patients with hypersensitivity to cenobamate should avoid XCOPRI. https://fda.einnews.com/pr_news/502878004/fda-approves-new-treatment-for-adults-with-partial-onset-seizures
